近日，FDA 发布了一份《开发用于治疗慢性疼痛的非阿片类镇痛药》的指南草案，目的在于加速开发安全有效的非阿片类药物，减少处方相关阿片类药物的滥用。这份指南草案远非一份普通的文件，而是为新型镇痛药的发展指明了方向，从监管层面引导全球药企从拥挤的红海转向疼痛管理这片广阔却长期被忽视的蓝海。| FDA 为什么鼓励开发非阿片类镇痛药？一方面，阿片类镇痛药本身具有较强的成瘾性，加之药物滥用现象屡禁不止，在...
Source Link近日，FDA 发布了一份《开发用于治疗慢性疼痛的非阿片类镇痛药》的指南草案，目的在于加速开发安全有效的非阿片类药物，减少处方相关阿片类药物的滥用。这份指南草案远非一份普通的文件，而是为新型镇痛药的发展指明了方向，从监管层面引导全球药企从拥挤的红海转向疼痛管理这片广阔却长期被忽视的蓝海。| FDA 为什么鼓励开发非阿片类镇痛药？一方面，阿片类镇痛药本身具有较强的成瘾性，加之药物滥用现象屡禁不止，在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.